Altimmune Inc. (NASDAQ: ALT) Hogging The Spotlight Today

    SBUX Stock
    SBUX Stock

    VHCP Management LLC recently announced the acquisition of new stake in Altimmune Inc. (NASDAQ:ALT). This fresh investment now brings its stake to 14.06% valued currently at $119.61 million. In addition, Baker Bros. Advisors LP raised its holdings by 2.11 million to 2.11 million shares. And Renaissance Technologies LLC has lifted its position by 50.03% or 0.31 million shares – to 0.93 million shares.

    With over 1.27 million Altimmune Inc. (ALT) shares trading Friday and a closing price of $17.62 on the day, the dollar volume was approximately $22.42 million. The shares have shown a negative weekly performance of -26.71% and its price on 08/28/20 lost nearly -3.29%. Currently, there are 32.91M common shares owned by the public and among those 23.89M shares have been available to trade.

    An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 3 analysts who have offered their price forecasts for ALT have a consensus price objective of $55.00. The analysts have set the share’s price value over the next 12 months at a high of $80.00 and a low of $35.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Altimmune Inc. stock is 2.00 for the next 12 months. But an upside of 77.97% will see the stock hit the forecast high price target while mean target price for the stock is $50.00.

    Insiders at the company have transacted a total of 26 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 15 of these insider trades were purchases, accounting for 2,878,221 shares. Insider sales of the common stock occurred on 11 occasions, with total insider shares sold totaling 240,081 shares.

    The top 3 mutual fund holders in Altimmune Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Invesco Health Care Fund. Vanguard Total Stock Market Index owns 0.53 million shares of the company’s stock, all valued at over $14.21 million. The company bought an additional 0.14 million shares recently to bring their total holdings to about 1.67% of the shares outstanding. Vanguard Extended Market Index Fu sold 326.0 shares to see its total holdings shrink to 0.18 million shares valued at over $4.89 million and representing 0.57% of the shares outstanding. Invesco Health Care Fund bought 0.17 million shares to bring its total holdings to over 0.17 million shares at a value of $4.4 million. Invesco Health Care Fund now owns shares totaling to 0.52% of the shares outstanding.

    Shares of Altimmune Inc. (NASDAQ: ALT) opened at $18.4447, up $0.22 from a prior closing price of $18.22. However, the script later closed the day at $17.62, down -3.29%. The company’s stock has a 5-day price change of -26.71% and 103.94% over the past three months. ALT shares are trading 832.28% year to date (YTD), with the 12-month market performance up to 755.34% higher. It has a 12-month low price of $1.51 and touched a high of $35.10 over the same period. Currently, 1.27 million shares have been traded, compared to an average intraday trading volume of 4.10 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -28.12%, -16.03%, and 132.26% respectively.

    Institutional ownership of Altimmune Inc. (NASDAQ: ALT) shares accounts for 40.60% of the company’s 32.91M shares outstanding. Mutual fund holders own 3.56%, while other institutional holders and individual stakeholders account for 38.09% and 20.55% respectively.

    It has a market capitalization of $599.78M and a beta (3y monthly) value of 1.94. The earnings-per-share (ttm) stands at -$2.21. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.13% over the week and 10.47% over the month.

    Analysts forecast that Altimmune Inc. (ALT) will achieve an EPS of -$0.8 for the current quarter, -$1.61 for the next quarter and $2.47 for 2021. The lowest estimate earnings-per-share for the quarter is -$1.16 while analysts give the company a high EPS estimate of -$0.45. Comparatively, EPS for the current quarter was -$0.73 a year ago. Earnings per share for the fiscal year are expected to increase by 89.50%, and 174.80% over the next financial year.

    If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate Altimmune Inc. (ALT) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 0 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”

    Looking at the support for the ALT, a number of firms have released research notes about the stock. Evercore ISI stated their Outperform rating for the stock in a research note on August 14, 2020, with the firm’s price target at. Piper Sandler coverage for the Altimmune Inc. (ALT) stock in a research note released on July 31, 2020 offered a Overweight rating with a price target of $80. JMP Securities was of a view on July 28, 2020 that the stock is Mkt Outperform, while ROTH Capital gave the stock Buy rating on February 24, 2020, issuing a price target of $13. ROTH Capital on their part issued Buy rating on July 19, 2019.


    Please enter your comment!
    Please enter your name here